Forxiga will be accepted to be used for the dual therapy with insulin while Suglat is going to be newly registered

The insurance benefit standard of diabetes drugs has been expanded. Followed by DPP-4 inhibitors, the dual therapy of a SGLT-2 inhibitor, ‘Forxiga(dapagliflozin),’ is also expected to be applied in the standard.

The Ministry of Health and Welfare has administratively notified an amendment for the ‘Detailed Matters for the Insurance Benefit Standard and Method(Drug)’ on the 16^th.

The Amendment...